author-photo

Osamu Kataoka

Takeda Pharmaceutical Company

10

Papers

274

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.

2011 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (24)
Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125

2011 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (20)
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554

2011 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (31)
Corrigendum to “Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554” [Bioorg. Med. Chem. 19 (2011) 4482–4498]

2011 Bioorganic & Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (2)
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure

2009 Life Sciences
Show All
- Source
- Cite
- Save
Citations (14)
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice

2009 British Journal of Pharmacology
Show All
- Source
- Cite
- Save
Citations (42)
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.

2009 European Journal of Pharmacology
Show All
- Source
- Cite
- Save
Citations (30)
Remède pour le diabète

2005
Show All
- Source
- Cite
- Save
Citations (0)